Actinium $ATNM Receives Orphan Drug Designation From FDA for Iomab-B in Treating Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients

Orphan Drug Designation Anticipated to Provide Faster Regulatory Review, Financial Incentives and Market Exclusivity Read more